198 related articles for article (PubMed ID: 23979925)
1. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.
Dai F; Shu L; Bian Y; Wang Z; Yang Z; Chu W; Gao S
Clin Drug Investig; 2013 Nov; 33(11):779-88. PubMed ID: 23979925
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
Hurwitz HI; Tebbutt NC; Kabbinavar F; Giantonio BJ; Guan ZZ; Mitchell L; Waterkamp D; Tabernero J
Oncologist; 2013; 18(9):1004-12. PubMed ID: 23881988
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.
Zhu X; Tian X; Yu C; Hong J; Fang J; Chen H
Medicine (Baltimore); 2016 Aug; 95(34):e4232. PubMed ID: 27559943
[TBL] [Abstract][Full Text] [Related]
4. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
[TBL] [Abstract][Full Text] [Related]
5. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.
Geiger-Gritsch S; Stollenwerk B; Miksad R; Guba B; Wild C; Siebert U
Oncologist; 2010; 15(11):1179-91. PubMed ID: 21045188
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
7. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis.
Wang M; Zheng X; Ruan X; Ye B; Cai L; Lin F; Tu J; Jiang F; Li S
Chin Med J (Engl); 2014; 127(3):538-46. PubMed ID: 24451964
[TBL] [Abstract][Full Text] [Related]
9. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
Cao Y; Tan A; Gao F; Liu L; Liao C; Mo Z
Int J Colorectal Dis; 2009 Jun; 24(6):677-85. PubMed ID: 19184059
[TBL] [Abstract][Full Text] [Related]
11. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Barni S
Med Oncol; 2013; 30(3):650. PubMed ID: 23828442
[TBL] [Abstract][Full Text] [Related]
12. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis.
Cai J; Ma H; Huang F; Zhu D; Bi J; Ke Y; Zhang T
World J Surg Oncol; 2013 Nov; 11():306. PubMed ID: 24283603
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.
Qi WX; Shen Z; Tang LN; Yao Y
Eur J Clin Pharmacol; 2014 Aug; 70(8):893-906. PubMed ID: 24858820
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Maspero F; Sauta MG; Beretta GD; Barni S
Clin Colorectal Cancer; 2013 Sep; 12(3):145-51. PubMed ID: 23763824
[TBL] [Abstract][Full Text] [Related]
17. Use of bevacizumab in the treatment of metastatic colorectal cancer.
Raouf S; Bridgewater J; Ellis R; Ferry D; Hill M; Wasan H
Br J Hosp Med (Lond); 2012 Jan; 73(1):25-30. PubMed ID: 22241406
[TBL] [Abstract][Full Text] [Related]
18. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.
Galfrascoli E; Piva S; Cinquini M; Rossi A; La Verde N; Bramati A; Moretti A; Manazza A; Damia G; Torri V; Muserra G; Farina G; Garassino MC;
Dig Liver Dis; 2011 Apr; 43(4):286-94. PubMed ID: 21146479
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
[TBL] [Abstract][Full Text] [Related]
20. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
Schutz FA; Jardim DL; Je Y; Choueiri TK
Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]